HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SIMPONI[®] (golimumab) safely and effectively. See full prescribing information for SIMPONI.

SIMPONI (golimumab) Injection, solution for subcutaneous use

Initial U.S. Approval: 2009

WARNINGS: SERIOUS INFECTIONS AND MALIGNANCY

- See full prescribing information for complete boxed warning.
- Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI (5.1).
- SIMPONI should be discontinued if a patient develops a serious infection or sepsis (5.1).
- Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI (5.1).
- Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1).
- Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI is a member (5.2).

-INDICATIONS AND USAGE----

SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of:

- Moderately to severely active Rheumatoid Arthritis (RA) in adults, in . combination with methotrexate (1.1)
- Active Psoriatic Arthritis (PsA) in adults, alone or in combination with methotrexate (1,2)
- Active Ankylosing Spondylitis in adults (AS) (1.3)

--DOSAGE AND ADMINISTRATION-

- Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis (2.1)
- 50 mg administered by subcutaneous injection once a month.
- -DOSAGE FORMS AND STRENGTHS-----
- 50 mg/0.5 mL in a single dose prefilled SmartJect[®] autoinjector (3)
- 50 mg/0.5 mL in a single dose prefilled syringe (3)

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNINGS: SERIOUS INFECTIONS and MALIGNANCY

- INDICATIONS AND USAGE 1
 - 1.1 Rheumatoid Arthritis
 - Psoriatic Arthritis 1.2
 - 1.3 Ankylosing Spondylitis
- DOSAGE AND ADMINISTRATION 2
 - Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis 2.1 Monitoring to Assess Safety 2.2
 - 23 General Considerations for Administration
 - DOSAGE FORMS AND STRENGTHS

CONTRAINDICATIONS

3

- WARNINGS AND PRECAUTIONS (see Boxed WARNING) 5
 - Serious Infections 5.1
 - Malignancies 5.2
 - 5.3 Congestive Heart Failure
 - Demyelinating Disorders 54
 - Use with Abatacept 5.5
 - Use with Anakinra 5.6
 - Switching Between Biological Disease Modifying Antirheumatic 5.7 Drugs (DMARDs)
 - 5.8 Hematologic Cytopenias
 - Vaccinations 5.9
 - 5.10 Hypersensitivity Reactions

ADVERSE REACTIONS

- Clinical Studies Experience 6.1
- Post-marketing Experience 6.2

DRUG INTERACTIONS

- -----CONTRAINDICATIONS-----
- None (4)
 - -----WARNINGS AND PRECAUTIONS-----
- Serious Infections Do not start SIMPONI during an active infection. If an infection develops, monitor carefully, and stop SIMPONI if infection becomes serious (5.1).
- Invasive fungal infections For patients who develop a systemic illness on SIMPONI, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic (5.1).
- Hepatitis B reactivation Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop SIMPONI and begin anti-viral therapy (5.1).
- Malignancies The incidence of lymphoma was seen more often than in the general U.S. population. Cases of other malignancies have been observed among patients receiving TNF-blockers (5.2).
- Heart failure Worsening, or new onset, may occur. Stop SIMPONI if new or worsening symptoms occur (5.3).
- Demyelinating disease, exacerbation or new onset, may occur (5.4).
- Hypersensitivity Reactions Serious systemic hypersensitivity reactions including anaphylaxis may occur (5.10).

----ADVERSE REACTIONS------Most common adverse reactions (incidence > 5%): upper respiratory tract infection, nasopharyngitis (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

- ----DRUG INTERACTIONS-----
- Abatacept increased risk of serious infection (5.1, 5.5, 7.2)
- Anakinra increased risk of serious infection (5.1, 5.6, 7.2).
- Live vaccines should not be given with SIMPONI (5.9, 7.3).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: XX11/2012

- 71 Methotrexate
- 7.2 Biologic Products for RA, PsA, and/or AS
- 7.3 Live Vaccines
- 7.4 Cytochrome P450 Substrates
- **USE IN SPECIFIC POPULATIONS**
- 8.1 Pregnancy

8

- Nursing Mothers 8.3
- Pediatric Use 8.4
- Geriatric Use 85
- **10 OVERDOSAGE**
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY
- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- CLINICAL STUDIES
- Rheumatoid Arthritis 141
 - 14.2 Psoriatic Arthritis 14.3 Ankylosing Spondylitis
- **15 REFERENCES**

16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION

- 17.1 Patient Counseling
- 17.2 Instruction on Injection Technique

*Sections or subsections omitted from the full prescribing information are not listed.

SFRI	WARNINGS: SERIOUS INFECTIONS and MALIGNANCY OUS INFECTIONS
Patie	nts treated with SIMPONI [®] are at increased risk for developing serious infection
	ead to hospitalization or death [see Warnings and Precautions (5.1)]. Most patient
	oped these infections were taking concomitant immunosuppressants suc otrexate or corticosteroids.
metn	offexate of conficosteroids.
SIMI	ONI should be discontinued if a patient develops a serious infection.
Repo	rted infections with TNF-blockers, of which SIMPONI is a member, include:
•	Active tuberculosis, including reactivation of latent tuberculosis. Patients
	tuberculosis have frequently presented with disseminated or extrapulmonary di
	Patients should be tested for latent tuberculosis before SIMPONI use and d
	therapy. Treatment for latent infection should be initiated prior to SIMPONI us
•	Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candid
•	aspergillosis, blastomycosis and pneumocystosis. Patients with histoplasmos
	other invasive fungal infections may present with disseminated, rather than loca
	disease. Antigen and antibody testing for histoplasmosis may be negative in
	patients with active infection. Empiric anti-fungal therapy should be consider
	patients at risk for invasive fungal infections who develop severe systemic illness
•	Bacterial, viral, and other infections due to opportunistic pathogens, incl
	Legionella and Listeria.
	isks and benefits of treatment with SIMPONI should be carefully considered pr
initia	ting therapy in patients with chronic or recurrent infection.
Datia	nts should be closely monitored for the development of signs and symptoms of info
	g and after treatment with SIMPONI, including the possible development
	culosis in patients who tested negative for latent tuberculosis infection pri
	ting therapy [see Warnings and Precautions (5.1)].
	ing merupy [see than migs and Precamons (ent)].
MAL	IGNANCY
Lym	bhoma and other malignancies, some fatal, have been reported in children
adole	scent patients treated with TNF blockers, of which SIMPONI is a member
Warn	ings and Precautions (5.2)].
1	INDICATIONS AND USAGE
1.1	Rheumatoid Arthritis
SUMP	ONI, in combination with methotrexate, is indicated for the treatment of adult patients

47

50

51 52

53

54 55

56 57

58 59

60

61

62 63

64

48 **1.2 Psoriatic Arthritis**49 SIMPONI, alone or in comb

SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis.

1.3 Ankylosing Spondylitis

SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis.

2 DOSAGE AND ADMINISTRATION

2.1 Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis

The SIMPONI dose regimen is 50 mg administered by subcutaneous injection once a month.

For patients with rheumatoid arthritis (RA), SIMPONI should be given in combination with methotrexate and for patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS), SIMPONI may be given with or without methotrexate or other non-biologic Disease Modifying Antirheumatic Drugs (DMARDs). For patients with RA, PsA, or AS, corticosteroids, non-biologic DMARDs, and/or NSAIDs may be continued during treatment with SIMPONI.

65 2.2 Monitoring to Assess Safety

Prior to initiating SIMPONI and periodically during therapy, patients should be evaluated for
 active tuberculosis and tested for latent infection [*see Warnings and Precautions (5.1)*]. Prior to
 initiating SIMPONI, patients should be tested for hepatitis B viral infection [*see Warnings and Precautions (5.1)*].

70 71

2.3 General Considerations for Administration

SIMPONI is intended for use under the guidance and supervision of a physician. After proper
 training in subcutaneous injection technique, a patient may self inject with SIMPONI if a
 physician determines that it is appropriate. Patients should be instructed to follow the directions
 provided in the Medication Guide (*see Medication Guide*). To ensure proper use, allow the
 prefilled syringe or autoinjector to sit at room temperature outside the carton for 30 minutes prior
 to subcutaneous injection. Do not warm SIMPONI in any other way.

Prior to administration, visually inspect the solution for particles and discoloration through the
viewing window. SIMPONI should be clear to slightly opalescent and colorless to light yellow.
The solution should not be used if discolored, or cloudy, or if foreign particles are present. Any
leftover product remaining in the prefilled syringe or prefilled autoinjector should not be used.

- 82 NOTE: The needle cover on the prefilled syringe as well as the prefilled syringe in the
- autoinjector contains dry natural rubber (a derivative of latex), which should not be handled by
 persons sensitive to latex.
- Injection sites should be rotated and injections should never be given into areas where the skin is
 tender, bruised, red, or hard.
- 87 88

89

3 DOSAGE FORMS AND STRENGTHS

90 SmartJect[®] Autoinjector

- Each single dose SmartJect autoinjector contains a prefilled glass syringe (27 gauge ½ inch)
 providing 50 mg of SIMPONI per 0.5 mL of solution.
- 93

- 94 Prefilled Syringe
 95 Each single dose prefilled glass syringe (27 gauge ½ inch) contains 50 mg of SIMPONI per 0.5
 96 mL of solution.
 - 4 **CONTRAINDICATIONS**
- 99 None.
- 100 101

103

104

105

119

120 121

122

123

124

125

97 98

5 WARNINGS AND PRECAUTIONS (see **Boxed WARNING**)

- 102 **5.1 Serious Infections**
 - Patients treated with SIMPONI are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.
- Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers. Patients have frequently presented with disseminated rather than localized disease. The concomitant use of a TNF-blocker and abatacept or anakinra was associated with a higher risk of serious infections; therefore, the concomitant use of SIMPONI and these biologic products is not recommended [*see Warnings and Precautions (5.5, 5.6) and Drug Interactions (7.2)*].
- 114 Treatment with SIMPONI should not be initiated in patients with an active infection, including 115 clinically important localized infections. Patients greater than 65 years of age, patients with co-116 morbid conditions and/or patients taking concomitant immunosuppressants such as corticosteroids 117 or methotrexate may be at greater risk of infection. The risks and benefits of treatment should be 118 considered prior to initiating SIMPONI in patients:
 - with chronic or recurrent infection;
 - who have been exposed to tuberculosis;
 - with a history of an opportunistic infection;
 - who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or
 - with underlying conditions that may predispose them to infection.

126 Monitoring

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with SIMPONI. SIMPONI should be discontinued if a patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with SIMPONI should undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored.

134 Serious Infection in Clinical Trials

In controlled Phase 3 trials through Week 16 in patients with RA, PsA, and AS, serious infections
were observed in 1.4% of SIMPONI-treated patients and 1.3% of control-treated patients. In the
controlled Phase 3 trials through Week 16 in patients with RA, PsA, and AS, the incidence of
serious infections per 100 patient-years of follow-up was 5.7 (95% CI: 3.8, 8.2) for the SIMPONI
group and 4.2 (95% CI: 1.8, 8.2) for the placebo group. Serious infections observed in SIMPONI-

140 treated patients included sepsis, pneumonia, cellulitis, abscess, tuberculosis, invasive fungal 141 infections, and hepatitis B infection.

143 **Tuberculosis**

144 Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients 145 receiving TNF-blockers, including patients who have previously received treatment for latent or 146 active tuberculosis. Patients should be evaluated for tuberculosis risk factors and tested for latent 147 infection prior to initiating SIMPONI and periodically during therapy.

148

154

142

149 Treatment of latent tuberculosis infection prior to therapy with TNF-blockers has been shown to 150 reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with 151 tuberculin skin testing should be considered a positive test result when assessing if treatment for 152 latent tuberculosis is needed prior to initiating SIMPONI, even for patients previously vaccinated 153 with Bacille Calmette-Guerin (BCG).

155 Anti-tuberculosis therapy should also be considered prior to initiation of SIMPONI in patients 156 with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot 157 be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors 158 for tuberculosis infection. Consultation with a physician with expertise in the treatment of 159 tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is 160 appropriate for an individual patient.

- 162 Patients should be closely monitored for the development of signs and symptoms of tuberculosis 163 including patients who tested negative for latent tuberculosis infection prior to initiating therapy.
- 164

161

165 Tuberculosis should be strongly considered in patients who develop a new infection during SIMPONI treatment, especially in patients who have previously or recently traveled to countries

166 167 with a high prevalence of tuberculosis, or who have had close contact with a person with active 168 tuberculosis. 169

170 In the controlled and uncontrolled portions of the Phase 2 RA and Phase 3 RA, PsA, and AS trials, 171 the incidence of active TB was 0.23 and 0 per 100 patient-years in 2347 SIMPONI-treated patients 172 and 674 placebo-treated patients, respectively. Cases of TB included pulmonary and extra 173 pulmonary TB. The overwhelming majority of the TB cases occurred in countries with a high 174 incidence rate of TB.

175

176 **Invasive Fungal Infections**

177 For SIMPONI-treated patients who reside or travel in regions where mycoses are endemic, 178 invasive fungal infection should be suspected if they develop a serious systemic illness. 179 Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being 180 performed. Antigen and antibody testing for histoplasmosis may be negative in some patients 181 with active infection. When feasible, the decision to administer empiric antifungal therapy in 182 these patients should be made in consultation with a physician with expertise in the diagnosis and 183 treatment of invasive fungal infections and should take into account both the risk for severe fungal 184 infection and the risks of antifungal therapy.

186 Hepatitis B Virus Reactivation

The use of TNF-blockers including SIMPONI has been associated with reactivation of hepatitis B
virus (HBV) in patients who are chronic hepatitis B carriers (i.e., surface antigen positive). In
some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been
fatal. The majority of these reports have occurred in patients who received concomitant
immunosuppressants.

192

202

193 All patients should be tested for HBV infection before initiating TNF-blocker therapy. For 194 patients who test positive for hepatitis B surface antigen, consultation with a physician with 195 expertise in the treatment of hepatitis B is recommended before initiating TNF-blocker therapy. 196 The risks and benefits of treatment should be considered prior to prescribing TNF-blockers. 197 including SIMPONI, to patients who are carriers of HBV. Adequate data are not available on 198 whether anti-viral therapy can reduce the risk of HBV reactivation in HBV carriers who are 199 treated with TNF-blockers. Patients who are carriers of HBV and require treatment with TNF-200 blockers should be closely monitored for clinical and laboratory signs of active HBV infection 201 throughout therapy and for several months following termination of therapy.

In patients who develop HBV reactivation, TNF-blockers should be stopped and antiviral therapy with appropriate supportive treatment should be initiated. The safety of resuming TNF-blockers after HBV reactivation has been controlled is not known. Therefore, prescribers should exercise caution when considering resumption of TNF-blockers in this situation and monitor patients closely.

209 5.2 Malignancies

210 Malignancies, some fatal, have been reported among children, adolescents, and young adults who 211 received treatment with TNF-blocking agents (initiation of therapy ≤ 18 years of age), of which 212 SIMPONI is a member. Approximately half the cases were lymphomas, including Hodgkin's and 213 non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression, and malignancies that are not 214 usually observed in children and adolescents. The malignancies occurred after a median of 30 215 216 months (range 1 to 84 months) after the first dose of TNF blocker therapy. Most of the patients 217 were receiving concomitant immunosuppressants. These cases were reported post-marketing and 218 are derived from a variety of sources, including registries and spontaneous postmarketing reports. 219

The risks and benefits of TNF-blocker treatment including SIMPONI should be considered prior to initiating therapy in patients with a known malignancy other than a successfully treated nonmelanoma skin cancer (NMSC) or when considering continuing a TNF-blocker in patients who develop a malignancy.

225 In the controlled portions of clinical trials of TNF-blockers including SIMPONI, more cases of 226 lymphoma have been observed among patients receiving anti-TNF treatment compared with patients in the control groups. During the controlled portions of the Phase 2 trials in RA, and the 227 228 Phase 3 trials in RA, PsA and AS, the incidence of lymphoma per 100 patient-years of follow-up 229 was 0.21 (95% CI: 0.03, 0.77) in the combined SIMPONI group compared with an incidence of 0 230 (95% CI: 0., 0.96) in the placebo group. In the controlled and uncontrolled portions of these 231 clinical trials in 2347 SIMPONI-treated patients with a median follow-up of 1.4 years, the 232 incidence of lymphoma was 3.8-fold higher than expected in the general U.S. population

according to the SEER database (adjusted for age, gender, and race).¹ Patients with RA and other 233 234 chronic inflammatory diseases, particularly patients with highly active disease and/or chronic 235 exposure to immunosuppressant therapies, may be at higher risk (up to several fold) than the 236 general population for the development of lymphoma, even in the absence of TNF-blocking 237 therapy. Cases of acute and chronic leukemia have been reported with postmarketing TNF-238 blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF blocker 239 therapy, patients with rheumatoid arthritis may be at a higher risk (approximately 2-fold) than the 240 general population for the development of leukemia.

During the controlled portions of the Phase 2 trial in RA, and the Phase 3 trials in RA, PsA and AS, the incidence of malignancies other than lymphoma per 100 patient-years of follow-up was not elevated in the combined SIMPONI group compared with the placebo group. In the controlled and uncontrolled portions of these trials, the incidence of malignancies, other than lymphoma, in SIMPONI-treated patients was similar to that expected in the general U.S. population according to the SEER database (adjusted for age, gender, and race).¹

In controlled trials of other TNF-blockers in patients at higher risk for malignancies (e.g., patients with COPD, patients with Wegener's granulomatosis treated with concomitant cyclophosphamide) a greater portion of malignancies occurred in the TNF-blocker group compared to the controlled group. In an exploratory 1-year clinical trial evaluating the use of 50, 100 and 200 mg of SIMPONI in 309 patients with severe persistent asthma, 6 patients developed malignancies other than NMSC in the SIMPONI groups compared to none in the control group. Three of the 6 patients were in the 200 mg SIMPONI group.

256 257

241

248

5.3 Congestive Heart Failure

258 Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with 259 TNF-blockers, including SIMPONI. In several exploratory trials of other TNF-blockers in the 260 treatment of CHF, there were greater proportions of TNF-blocker treated patients who had CHF 261 exacerbations requiring hospitalization or increased mortality. SIMPONI has not been studied in 262 patients with a history of CHF and SIMPONI should be used with caution in patients with CHF. 263 If a decision is made to administer SIMPONI to patients with CHF, these patients should be 264 closely monitored during therapy, and SIMPONI should be discontinued if new or worsening 265 symptoms of CHF appear.

266 267

5.4 Demyelinating Disorders

268 Use of TNF-blockers, of which SIMPONI is a member, has been associated with rare cases of new 269 onset or exacerbation of central nervous system (CNS) demyelinating disorders, including 270 multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barré 271 syndrome. Cases of central demyelination, MS, optic neuritis, and peripheral demyelinating 272 polyneuropathy have rarely been reported in patients treated with SIMPONI [see Adverse 273 *Reactions* (6.1)*I*. Prescribers should exercise caution in considering the use of TNF-blockers, 274 including SIMPONI, in patients with central or peripheral nervous system demyelinating 275 disorders. Discontinuation of SIMPONI should be considered if these disorders develop.

- 276 277
- 5.5 Use with Abatacept

In controlled trials, the concurrent administration of another TNF-blocker and abatacept was associated with a greater proportion of serious infections than the use of a TNF-blocker alone; and the combination therapy, compared to the use of a TNF-blocker alone, has not demonstrated improved clinical benefit in the treatment of RA. Therefore, the combination of TNF-blockers including SIMPONI and abatacept is not recommended [*see Drug Interactions (7.2)*].

284 **5.6 Use with Anakinra**

Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocker, was associated with a greater portion of serious infections and neutropenia and no additional benefits compared with the TNF-blocker alone. Therefore, the combination of anakinra with TNFblockers, including SIMPONI, is not recommended [*see Drug Interactions* (7.2)].

289 290

291

292

293

294

300

5.7 Switching Between Biological Disease Modifying Antirheumatic Drugs (DMARDs)

Care should be taken when switching from one biologic to another since overlapping biological activity may further increase the risk of infection.

5.8 Hematologic Cytopenias

There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers. In clinical studies, cases of pancytopenia, leukopenia, neutropenia, and thrombocytopenia have also occurred in SIMPONItreated patients. Caution should be exercised when using TNF-blockers, including SIMPONI, in patients who have or have had significant cytopenias.

301 **5.9 Vaccinations**

Patients treated with SIMPONI may receive vaccinations, except for live vaccines. No data are 302 303 available on the response to live vaccination or the risk of infection, or transmission of infection 304 after the administration of live vaccines to patients receiving SIMPONI. In the Phase 3 PsA study, after pneumococcal vaccination, a similar proportion of SIMPONI-treated and placebo-treated 305 patients were able to mount an adequate immune response of at least a 2-fold increase in antibody 306 307 titers to pneumococcal polysaccharide vaccine. In both SIMPONI-treated and placebo-treated 308 patients, the proportions of patients with response to pneumococcal vaccine were lower among 309 patients receiving MTX compared with patients not receiving MTX. The data suggest that 310 SIMPONI does not suppress the humoral immune response to the pneumococcal vaccine.

5.10 Hypersensitivity Reactions

In post-marketing experience, serious systemic hypersensitivity reactions (including anaphylactic reaction) have been reported following SIMPONI administration. Some of these reactions occurred after the first administration of SIMPONI. If an anaphylactic or other serious allergic reaction occurs, administration of SIMPONI should be discontinued immediately and appropriate therapy instituted.

318 319

323

311312

6 ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates
 observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of
 another drug and may not reflect the rates observed in clinical practice.

324 6.1 Clinical Studies Experience

325 The safety data described below are based on 5 pooled, randomized, double-blind, controlled 326 Phase 3 trials in patients with RA, PsA, and AS (Studies RA-1, RA-2, RA-3, PsA, and AS) [see 327 *Clinical Studies (14.1, 14.2 and 14.3)*]. These 5 trials included 639 control-treated patients and 1659 SIMPONI-treated patients including 1089 with RA, 292 with PsA, and 278 with AS. The 328 329 proportion of patients who discontinued treatment due to adverse reactions in the controlled Phase 330 3 trials through Week 16 in RA, PsA and AS was 2% for SIMPONI-treated patients and 3% for 331 placebo-treated patients. The most common adverse reactions leading to discontinuation of 332 SIMPONI in the controlled Phase 3 trials through Week 16 were sepsis (0.2%), alanine 333 aminotransferase increased (0.2%), and aspartate aminotransferase increased (0.2%). 334

- The most serious adverse reactions were:
 - Serious Infections [see Warnings and Precautions (5.1)]
 - Malignancies [see Warnings and Precautions (5.2)]

Upper respiratory tract infection and nasopharyngitis were the most common adverse reactions
reported in the combined Phase 3 RA, PsA and AS trials through Week 16, occurring in 7% and
6% of SIMPONI-treated patients as compared with 6% and 5% of control-treated patients,
respectively.

Infections

335

336

337

338

343 344

348

357

367

In controlled Phase 3 trials through Week 16 in RA, PsA, and AS, infections were observed in
28% of SIMPONI-treated patients compared to 25% of control-treated patients [for Serious
Infections, *see Warnings and Precautions (5.1)*].

349 *Liver Enzyme Elevations*

There have been reports of severe hepatic reactions including acute liver failure in patients receiving TNF-blockers. In controlled Phase 3 trials of SIMPONI in patients with RA, PsA, and AS through Week 16, ALT elevations $\geq 5 \times ULN$ occurred in 0.2% of control-treated patients and 0.7% of SIMPONI-treated patients and ALT elevations $\geq 3 \times ULN$ occurred in 2% of controltreated patients and 2% of SIMPONI-treated patients. Since many of the patients in the Phase 3 trials were also taking medications that cause liver enzyme elevations (e.g., NSAIDs, MTX), the relationship between SIMPONI and liver enzyme elevation is not clear.

358 Autoimmune Disorders and Autoantibodies

359 The use of TNF-blockers, including SIMPONI, has been associated with the formation of 360 autoantibodies and, rarely, with the development of a lupus-like syndrome. In the controlled 361 Phase 3 trials in patients with RA, PsA, and AS through Week 14, there was no association of 362 SIMPONI treatment and the development of newly positive anti-dsDNA antibodies. In Phase 3 trials in RA, PsA, and AS through 1 year of follow up, 4.0% of SIMPONI-treated patients and 363 364 2.6% of control patients were newly ANA-positive (at titers of 1:160 or greater). The frequency 365 of anti-dsDNA antibodies at 1 year of follow up was uncommon in patients who were anti-dsDNA 366 negative at baseline.

368 Injection Site Reactions

In controlled Phase 3 trials through Week 16 in RA, PsA and AS, 6% of SIMPONI-treated
 patients had injection site reactions compared with 2% of control-treated patients. The majority of

the injection site reactions were mild and the most frequent manifestation was injection site
erythema. In controlled Phase 2 and 3 trials in RA, PsA, and AS, no patients treated with
SIMPONI developed anaphylactic reactions.

375 *Immunogenicity*

374

385

376 Antibodies to SIMPONI were detected in 57 (4%) of SIMPONI-treated patients across the Phase 3 377 RA, PsA, and AS trials through Week 24. Similar rates were observed in each of the three 378 indications. Patients who received SIMPONI with concomitant MTX had a lower proportion of 379 antibodies to SIMPONI than patients who received SIMPONI without MTX (approximately 2% 380 versus 7%, respectively). Of the patients with a positive antibody response to SIMPONI in the 381 Phase 2 and 3 trials, most were determined to have neutralizing antibodies to golimumab as 382 measured by a cell-based functional assay. The small number of patients positive for antibodies to SIMPONI limits the ability to draw definitive conclusions regarding the relationship between 383 384 antibodies to golimumab and clinical efficacy or safety measures.

The data above reflect the percentage of patients whose test results were considered positive for antibodies to SIMPONI in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SIMPONI with the incidence of antibodies to other products may be misleading.

393 Other Adverse Reactions

394Table 1 summarizes the adverse drug reactions that occurred at a rate of at least 1% in the395SIMPONI ± DMARD group and with a higher incidence than in the placebo ± DMARD group396during the controlled period of the 5 pooled Phase 3 trials through Week 16 in patients with RA,397PsA, and AS.

398

392

Table 1. Adverse Drug Reactions Reported by ≥ 1% of SIMPONI-Treated Patients and with a Higher Incidence than Placebo-Treated Patients in the Phase 3 Trials of RA, PsA, and AS through Week 16^a

	SIMPONI ± DMARDs	Placebo ± DMARDs
Patients treated	1659	639
Adverse Reaction		
Infections and Infestations		
Upper respiratory tract infection (nasopharyngitis, pharyngitis, laryngitis, and rhinitis)	16%	13%
Viral infections (such as influenza and herpes)	5%	3%
Bronchitis	2%	1%
Superficial fungal infections	2%	1%
Sinusitis	2%	1%

Table 1. Adverse Drug Reactions Reported by ≥ 1% of SIMPONI-Treated Patients and with a Higher Incidence than Placebo-Treated Patients in the Phase 3 Trials of RA, PsA, and AS through Week 16^a

General disorders and administration site conditions Injection site reaction (injection site 6% 2% erythema, uritaria, induration, pain, bruising, puritus, irritation, parasthesia) Investigations Alanine aminotransferase increased 4% 3% Aspartate aminotransferase 3% 2% increased Hypertension 3% 2% Vascular disorders Hypertension 3% 2% Dizziness 2% 1% Paresthesia 2% 1% Gastrointestinal Disorders 2% 1% Constipation 1% <1% a Patients may have taken concomitant MTX, sulfasalazine, hydroxychloroquine, low dose corticosteroids (≤ 10 mg o prednisone/day or equivalent), and/or NSAUDs during the trials). Less common clinical trial adverse drug reactions Adverse drug reactions that occurred <1% in SIMPONI-treated patients during the SIMPONI clinical trials during and precautions section included the following events listed by system organ class: Infections and infestations: Septic shock, atypical mycobacterial infection, pyelonephritis, arth bacterial, bursitis infective Neoplasms benign, malignant and unspecified: leukemia Skin and subcutaneous tissue disorders: psoriasis (new onset or worsening, palmat/plantar and pustu			SIMPONI ± DMARDs	Placebo ± DMARDs
Injection site reaction (injection site 6% 2% erythema, urticaria, induration, pain, bruising, pruritus, irritation, paresthesia) Investigations Alanine aminotransferase increased 4% 3% Aspartate aminotransferase increased 4% 3% Aspartate aminotransferase 3% 2% increased 1% 2% Vascular disorders 1% 1% Hypertension 3% 2% Paresthesia 2% 1% Gastrointestinal Disorders 1% 6 Onstigation 1% <1%				
erythema, urticaria, induration, pain, bruising, pruritus, irritation, paresthesia) Investigations Alanine aminotransferase increased 4% 3% Aspartate aminotransferase increased 4% 2% increased Vascular disorders Hypertension 3% 2% Nervous system disorders Dizziness 2% 1% Gastrointestinal Disorders Constipation 1% <1% a Patients may have taken concomitant MTX, sulfasalazine, hydroxychloroquine, low dose corticosteroids (≤ 10 mg o prednisone/day or equivalent), and/or NSAIDs during the trials). Less common clinical trial adverse drug reactions Adverse drug reactions that occurred <1% in SIMPONI-treated patients during the SIMPONI clinical trials that do not appear in the Warnings and Precautions section included the following events listed by system organ class: Infections and infestations: Septic shock, atypical mycobacterial infection, pyelonephritis, arth bacterial, bursitis infective Neoplasms benign, malignant and unspecified: leukemia Skin and subcutaneous tissue disorders: psoriasis (new onset or worsening, palmar/plantar and pustular), vasculitis (cutaneous) Vascular disorders: Vasculitis (systemic) 6.2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of SIMPONI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPON. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPON. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPON. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPON exposure.			<i>co (</i>	
bruising, pruritus, irritation, paresthesia) Investigations Alanine aminotransferase increased 4% 3% Aspartate aminotransferase increased 4% 3% Aspartate aminotransferase increased 4% 3% Aspartate aminotransferase 3% 2% Increased Vascular disorders Hypertension 3% 2% Nervous system disorders Dizziness 2% 1% Gastrointestinal Disorders Constipation 1% <1% a Patients may have taken concomitant MTX, sulfasalazine, hydroxychloroquine, low dose corticosteroids (≤ 10 mg o prednisone/day or equivalent), and/or NSAIDs during the trials). Less common clinical trial adverse drug reactions Adverse drug reactions that occurred <1% in SIMPONI-treated patients during the SIMPONI clinical trials that do not appear in the Warnings and Precautions section included the following events listed by system organ class: Infections and infestations: Septic shock, atypical mycobacterial infection, pyelonephritis, arth bacterial, bursitis infective Neoplasms benign, malignant and unspecified: leukemia Skin and subcutaneous tissue disorders: poriasis (new onset or worsening, palmar/plantar and pustular), vasculitis (cutaneous) Vascular disorders: Vasculitis (systemic) C.1 Post-marketing Experience The following adverse reactions have been identified during post-approval use of SIMPONI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPO exposure. Immune System Disorders: Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see Warnings and Precautions (5.10)], sarcoidosis			6%	2%
paresthesia) Investigations Alanine aminotransferase increased 4% 3% Aspartate aminotransferase 3% 2% increased 7% 2% Vascular disorders 8% 2% Hypertension 3% 2% Dizziness 2% 1% Paresthesia 2% 1% Constipation 1% <1%				
Alanine aminotransferase increased 4% 3% Aspartate aminotransferase 3% 2% increased 3% 2% Vascular disorders 1% 2% Hypertension 3% 2% Dizziness 2% 1% Paresthesia 2% 1% Constipation 1% <1%	ŗ	paresthesia)		
Aspartate aminotransferase 3% 2% increased Vascular disorders Hypertension 3% 2% Nervous system disorders Dizziness 2% Dizziness 2% 1% Paresthesia 2% 1% Gastrointestinal Disorders 1% <1%				
increased Vascular disorders Hypertension 3% 2% Nervous system disorders Dizziness 2% 1% Darsthesia 2% 1% Paresthesia 2% 1% Gastrointestinal Disorders 2% 1% Constipation 1% <1%				
Hypertension 3% 2% Nervous system disorders Dizziness 2% Dizziness 2% 1% Paresthesia 2% 1% Gastrointestinal Disorders 2% 1% Constipation 1% <1%			3%	2%
Nervous system disorders Dizziness 2% 1% Paresthesia 2% 1% Gastrointestinal Disorders 2% 1% Constipation 1% <1%	Vaso	cular disorders		
Dizziness 2% 1% Paresthesia 2% 1% Gastrointestinal Disorders 2% 1% Constipation 1% <1%	I	Hypertension	3%	2%
Paresthesia 2% 1% Gastrointestinal Disorders Constipation 1% <1%				
Gastrointestinal Disorders Constipation 1% <1%				
Constipation 1% <1%			2%	1%
 a Patients may have taken concomitant MTX, sulfasalazine, hydroxychloroquine, low dose corticosteroids (≤ 10 mg o prednisone/day or equivalent), and/or NSAIDs during the trials). Less common clinical trial adverse drug reactions Adverse drug reactions that occurred <1% in SIMPONI-treated patients during the SIMPONI clinical trials that do not appear in the Warnings and Precautions section included the following events listed by system organ class: <p>Infections and infestations: Septic shock, atypical mycobacterial infection, pyelonephritis, arth bacterial, bursitis infective Neoplasms benign, malignant and unspecified: leukemia Skin and subcutaneous tissue disorders: psoriasis (new onset or worsening, palmar/plantar and pustular), vasculitis (cutaneous) Vascular disorders: Vasculitis (systemic) 6.2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of SIMPONI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPO exposure. </p> 				
 prednisone/day or equivalent), and/or NSAIDs during the trials). Less common clinical trial adverse drug reactions Adverse drug reactions that occurred <1% in SIMPONI-treated patients during the SIMPONI clinical trials that do not appear in the Warnings and Precautions section included the following events listed by system organ class: Infections and infestations: Septic shock, atypical mycobacterial infection, pyelonephritis, arth bacterial, bursitis infective Neoplasms benign, malignant and unspecified: leukemia Skin and subcutaneous tissue disorders: psoriasis (new onset or worsening, palmar/plantar and pustular), vasculitis (cutaneous) Vascular disorders: Vasculitis (systemic) 6.2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of SIMPONI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPO exposure. Immune System Disorders: Serious systemic hypersensitivity reactions (including anaphylaction reaction) [see Warnings and Precautions (5.10)], sarcoidosis 				
 Vascular disorders: Vasculitis (systemic) 6.2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of SIMPONI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPO exposure. Immune System Disorders: Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see Warnings and Precautions (5.10)], sarcoidosis]	Infections and infestations: Septic bacterial, bursitis infective Neoplasms benign, malignant and Skin and subcutaneous tissue diso	shock, atypical mycobacteria	
 6.2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of SIMPONI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPC exposure. <i>Immune System Disorders:</i> Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see Warnings and Precautions (5.10)], sarcoidosis 	-			
 The following adverse reactions have been identified during post-approval use of SIMPONI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPC exposure. <i>Immune System Disorders:</i> Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see Warnings and Precautions (5.10)], sarcoidosis 		Vascular disorders: Vasculitis (sy	ystemic)	
 The following adverse reactions have been identified during post-approval use of SIMPONI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPC exposure. <i>Immune System Disorders:</i> Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see Warnings and Precautions (5.10)], sarcoidosis 				
 Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPC exposure. <i>Immune System Disorders:</i> Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see Warnings and Precautions (5.10)], sarcoidosis 		81		
 always possible to reliably estimate their frequency or establish a causal relationship to SIMPC exposure. <i>Immune System Disorders:</i> Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see Warnings and Precautions (5.10)], sarcoidosis 		-		
exposure. <i>Immune System Disorders:</i> Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see Warnings and Precautions (5.10)], sarcoidosis		-	• • • •	
<i>Immune System Disorders:</i> Serious systemic hypersensitivity reactions (including anaphylactic reaction) [<i>see Warnings and Precautions (5.10)</i>], sarcoidosis			te their frequency or establish	a causal relationship to SIMPC
reaction) [see Warnings and Precautions (5.10)], sarcoidosis		exposure.		
reaction) [see Warnings and Precautions (5.10)], sarcoidosis				
		Immune System Disorders: Serio	ua avatamia hyporgonaitivity ra	partiana (including anonhylactic
Skin and subcutaneous tissue disorders: Skin exfoliation	1	2	5 51 5	factions (including anaphylactic
		reaction) [see Warnings and Prece	autions (5.10)], sarcoidosis	
	,	reaction) [see Warnings and Prece	autions (5.10)], sarcoidosis	

- 423
- 424 **7 DRUG INTERACTIONS**

425 **7.1 Methotrexate**

For the treatment of RA, SIMPONI should be used with methotrexate (MTX) [*see Clinical Studies* (14.1)]. Since the presence or absence of concomitant MTX did not appear to influence the efficacy or safety of SIMPONI in the treatment of PsA or AS, SIMPONI can be used with or without MTX in the treatment of PsA and AS [*see Clinical Studies* (14.1) and Clinical *Pharmacology* (12.3)].

431

432 7.2 Biologic Products for RA, PsA, and/or AS

An increased risk of serious infections has been seen in clinical RA studies of other TNF-blockers used in combination with anakinra or abatacept, with no added benefit; therefore, use of SIMPONI with abatacept or anakinra is not recommended [*see Warnings and Precautions (5.5 and 5.6)*]. A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF-blocker. The concomitant use of SIMPONI with biologics approved to treat RA, PsA, or AS is not recommended because of the possibility of an increased risk of infection.

440

444

441 7.3 Live Vaccines

442 Live vaccines should not be given concurrently with SIMPONI [*see Warnings and Precautions*443 (5.9)].

Infants born to women treated with SIMPONI during their pregnancy may be at increased risk of
infection for up to 6 months. Administration of live vaccines to infants exposed to SIMPONI *in utero* is not recommended for 6 months following the mother's last SIMPONI injection during
pregnancy (*see Use in Specific Populations (8.1*)].

449 450

7.4 Cytochrome P450 Substrates

451 The formation of CYP450 enzymes may be suppressed by increased levels of cytokines 452 (e.g., $TNF\alpha$) during chronic inflammation. Therefore, it is expected that for a molecule that 453 antagonizes cytokine activity, such as golimumab, the formation of CYP450 enzymes could be 454 normalized. Upon initiation or discontinuation of SIMPONI in patients being treated with 455 CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or 456 drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of 457 the drug product may be adjusted as needed.

458 459

8 USE IN SPECIFIC POPULATIONS

460 **8.1 Pregnancy**

Pregnancy Category B – There are no adequate and well-controlled studies of SIMPONI in
pregnant women. Because animal reproduction and developmental studies are not always
predictive of human response, it is not known whether SIMPONI can cause fetal harm when
administered to a pregnant woman or can affect reproduction capacity. SIMPONI should be used
during pregnancy only if clearly needed.

466

467 An embryofetal developmental toxicology study was performed in which pregnant cynomolgus 468 monkeys were treated subcutaneously with golimumab during the first trimester with doses up to 469 50 mg/kg twice weekly (360 times greater than the maximum recommended human dose-MHRD)

470 and has revealed no evidence of harm to maternal animals or fetuses. Umbilical cord blood

471 samples collected at the end of the second trimester showed that fetuses were exposed to
472 golimumab during gestation. In this study, *in utero* exposure to golimumab produced no
473 developmental defects to the fetus.

A pre- and post-natal developmental study was performed in which pregnant cynomolgus
monkeys were treated with golimumab during the second and third trimesters, and during lactation
at doses up to 50 mg/kg twice weekly (860 times and 310 times greater than the maximal steady
state human blood levels for maternal animals and neonates, respectively) and has revealed no
evidence of harm to maternal animals or neonates. Golimumab was present in the neonatal serum
from the time of birth and for up to six months postpartum. Exposure to golimumab during
gestation and during the postnatal period caused no developmental defects in the infants.

- IgG antibodies are known to cross the placenta during pregnancy and have been detected in the serum of infants born to patients treated with these antibodies. Since SIMPONI is an IgG antibody, infants born to women treated with SIMPONI during their pregnancy may be at increased risk of infection for up to 6 months. Administration of live vaccines to infants exposed to SIMPONI *in utero* is not recommended for 6 months following the mother's last SIMPONI injection during pregnancy [*see Warnings and Precautions (5.9)*].
- 490 **8.3** Nursing Mothers
- It is not known whether SIMPONI is excreted in human milk or absorbed systemically after
 ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of
 the potential for adverse reactions in nursing infants from SIMPONI, a decision should be made
 whether to discontinue nursing or to discontinue the drug, taking into account the importance of
 the drug to the mother.
- 496

501

503

504

474

482

489

In the pre- and post-natal development study in cynomolgus monkeys in which golimumab was
 administered subcutaneously during pregnancy and lactation, golimumab was detected in the
 breast milk at concentrations that were approximately 400-fold lower than the maternal serum
 concentrations.

502 **8.4 Pediatric Use**

Safety and effectiveness of SIMPONI in pediatric patients less than 18 years of age have not been established.

505 506

8.5 Geriatric Use

507 In the Phase 3 trials in RA, PsA, and AS, there were no overall differences in SAEs, serious 508 infections, and AEs in SIMPONI-treated patients ages 65 or older (N = 155) compared with 509 younger SIMPONI-treated patients. Because there is a higher incidence of infections in the 510 geriatric population in general, caution should be used in treating geriatric patients with 511 SIMPONI.

512

513 **10 OVERDOSAGE**

514 In a clinical study, 5 patients received protocol-directed single infusions of 10 mg/kg of 515 intravenous SIMPONI without serious adverse reactions or other significant reactions. The highest weight patient was 100 kg, and therefore received a single intravenous infusion of 1000
mg of SIMPONI. There were no SIMPONI overdoses in the clinical studies.

519 **11 DESCRIPTION**

SIMPONI (golimumab) is a human IgG1κ monoclonal antibody specific for human tumor
 necrosis factor alpha (TNFα) that exhibits multiple glycoforms with molecular masses of
 approximately 150 to 151 kilodaltons. SIMPONI was created using genetically engineered mice
 immunized with human TNF, resulting in an antibody with human-derived antibody variable and
 constant regions. SIMPONI is produced by a recombinant cell line cultured by continuous
 perfusion and is purified by a series of steps that includes measures to inactivate and remove
 viruses.

527

518

The SIMPONI drug product is a sterile solution of the golimumab antibody supplied as either a single dose prefilled syringe (with a passive needle safety guard) or a single dose prefilled autoinjector. The Type 1 glass syringe has a coated stopper. The fixed stainless steel needle (5 bevel, 27G, half-inch) is covered with a needle shield to prevent leakage of the solution through the needle and to protect the needle during handling prior to administration. The needle shield is made of a dry natural rubber containing latex.

SIMPONI does not contain preservatives. The solution is clear to slightly opalescent, colorless to
light yellow with a pH of approximately 5.5. SIMPONI is provided in one strength: 50 mg of the
golimumab antibody in 0.5 mL of solution. Each 0.5 mL of SIMPONI contains 50 mg of the
golimumab antibody, 0.44 mg of L-histidine and L-histidine monohydrochloride monohydrate,
20.5 mg of sorbitol, 0.08 mg of polysorbate 80, and Water for Injection.

540 541

12 CLINICAL PHARMACOLOGY

542 **12.1 Mechanism of Action**

543 Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane 544 bioactive forms of human TNF α . This interaction prevents the binding of TNF α to its receptors, 545 thereby inhibiting the biological activity of TNF α (a cytokine protein). There was no evidence of 546 the golimumab antibody binding to other TNF superfamily ligands; in particular, the golimumab 547 antibody did not bind or neutralize human lymphotoxin. Golimumab did not lyse human 548 monocytes expressing transmembrane TNF in the presence of complement or effector cells. 549

Elevated TNF α levels in the blood, synovium, and joints have been implicated in the pathophysiology of several chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. TNF α is an important mediator of the articular inflammation that is characteristic of these diseases. Golimumab modulated the *in vitro* biological effects mediated by TNF in several bioassays, including the expression of adhesion proteins responsible for leukocyte infiltration (E-selectin, ICAM-1 and VCAM-1) and the secretion of proinflammatory cytokines (IL-6, IL-8, G-CSF and GM-CSF).

557

558 **12.2 Pharmacodynamics**

In clinical studies, decreases in C-reactive protein (CRP), interleukin (IL)-6, matrix
 metalloproteinase 3 (MMP-3), intercellular adhesion molecule (ICAM)-1 and vascular endothelial

growth factor (VEGF) were observed following SIMPONI administration in patients with RA,PsA, and AS.

564 **12.3 Pharmacokinetics**

563

579

565 Following subcutaneous administration of SIMPONI to healthy subjects and patients with active 566 RA, the median time to reach maximum serum concentrations (T_{max}) ranged from 2 to 6 days. A 567 subcutaneous injection of 50 mg SIMPONI to healthy subjects produced a mean maximum serum 568 concentration (C_{max}) of approximately 2.5 µg/mL. SIMPONI exhibited dose-proportional 569 pharmacokinetics (PK) in patients with active RA over the dose range of 0.1 to 10.0 mg/kg 570 following a single intravenous (IV) dose. Following a single IV administration over the same 571 dose range in patients with active RA, mean systemic clearance of SIMPONI was estimated to be 572 4.9 to 6.7 mL/day/kg, and mean volume of distribution ranged from 58 to 126 mL/kg. The 573 volume of distribution for SIMPONI indicates that SIMPONI is distributed primarily in the 574 circulatory system with limited extravascular distribution. Median terminal half-life values were 575 estimated to be approximately 2 weeks in healthy subjects and patients with active RA, PsA or 576 AS. By cross-study comparisons of mean AUC_{inf} values following an IV or subcutaneous 577 administration of SIMPONI, the absolute bioavailability of subcutaneous SIMPONI was estimated 578 to be approximately 53%.

580 When 50 mg SIMPONI was administered subcutaneous to patients with RA, PsA, or AS every 4 581 weeks, serum concentrations appeared to reach steady state by Week 12. With concomitant use of 582 methotrexate (MTX), treatment with 50 mg SIMPONI subcutaneous every 4 weeks resulted in a 583 mean steady-state trough serum concentration of approximately 0.4-0.6 µg/mL in patients with 584 active RA, approximately 0.5 µg/mL in patients with active PsA, and approximately 0.8 µg/mL in 585 patients with active AS. Patients with RA, PsA, and AS treated with SIMPONI 50 mg and MTX 586 had approximately 52%, 36% and 21% higher mean steady-state trough concentrations of golimumab, respectively compared with those treated with SIMPONI 50 mg without MTX. The 587 588 presence of MTX also decreased anti-golimumab antibody incidence from 7% to 2% [see Adverse 589 *Reactions* (6.1)]. For RA, SIMPONI should be used with MTX. In the PsA and AS trials, the 590 presence or absence of concomitant MTX did not appear to influence clinical efficacy and safety 591 parameters [see Drug Interactions (7.1) and Clinical Studies (14.1)].

Population PK analyses indicated that concomitant use of NSAIDs, oral corticosteroids, or
 sulfasalazine did not influence the apparent clearance of SIMPONI.

Population PK analyses showed there was a trend toward higher apparent clearance of SIMPONI
with increasing weight. However, across the PsA and AS populations, no meaningful differences
in clinical efficacy were observed among the subgroups by weight quartile. The RA trial in MTXexperienced and TNF-blocker-naïve patients (Study RA-2) did show evidence of a reduction in
clinical efficacy with increasing body weight, but this effect was observed for both tested doses of
SIMPONI (50 mg and 100 mg). Therefore, there is no need to adjust the dosage of SIMPONI
based on a patient's weight.

603

592

595

Population PK analyses suggested no PK differences between male and female patients after body
 weight adjustment in the RA and PsA trials. In the AS trial, female patients showed 13% higher
 apparent clearance than male patients after body weight adjustment. Subgroup analysis based on

gender showed that both female and male patients achieved clinically significant response at the
 proposed clinical dose. Dosage adjustment based on gender is not needed.

610Population PK analyses indicated that PK parameters of SIMPONI were not influenced by age in611adult patients. Patients with age \geq 65 years had apparent clearance of SIMPONI similar to612patients with age < 65 years. No ethnicity-related PK differences were observed between</td>613Caucasians and Asians, and there were too few patients of other races to assess for PK differences.

- 615 Patients who developed anti-SIMPONI antibodies generally had lower steady-state serum trough 616 concentrations of SIMPONI.
- 617 618

619

620

621 622

627

628 629

614

No formal study of the effect of renal or hepatic impairment on the PK of golimumab was conducted.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

623Long-term animal studies of golimumab have not been conducted to evaluate its carcinogenic624potential. Mutagenicity studies have not been conducted with golimumab. A fertility study625conducted in mice using an analogous anti-mouse TNF α antibody showed no impairment of626fertility.

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

630 The efficacy and safety of SIMPONI were evaluated in 3 multicenter, randomized, double-blind, 631 controlled trials (Studies RA-1, RA-2, and RA-3) in 1542 patients \geq 18 years of age with moderately to severely active RA, diagnosed according to the American College of Rheumatology 632 (ACR) criteria, for at least 3 months prior to administration of study agent. Patients were required 633 634 to have at least 4 swollen and 4 tender joints. SIMPONI was administered subcutaneously at doses of 50 mg or 100 mg every 4 weeks. Double-blinded controlled efficacy data were collected 635 636 and analyzed through Week 24. Patients were allowed to continue stable doses of concomitant low dose corticosteroids (equivalent to ≤ 10 mg of prednisone a day) and/or NSAIDs and patients 637 638 may have received oral MTX during the trials.

640Study RA-1 evaluated 445 patients who were previously treated (at least 8 to 12 weeks prior to641administration of study agent) with one or more doses of a biologic TNF-blocker without a serious642adverse reaction. Patients may have discontinued the biologic TNF-blocker for a variety of643reasons. Patients were randomized to receive placebo (n = 150), SIMPONI 50 mg (n = 147), or644SIMPONI 100 mg (n = 148). Patients were allowed to continue stable doses of concomitant645MTX, sulfasalazine (SSZ), and/or hydroxychloroquine (HCQ) during the trial. The use of other646DMARDs including cytotoxic agents or other biologics was prohibited.

647

639

Study RA-2 evaluated 444 patients who had active RA despite a stable dose of at least 15
mg/week of MTX and who had not been previously treated with a biologic TNF-blocker. Patients
were randomized to receive background MTX (n = 133), SIMPONI 50 mg + background MTX (n
= 89), SIMPONI 100 mg + background MTX (n = 89), or SIMPONI 100 mg monotherapy (n =

133). The use of other DMARDs including SSZ, HCQ, cytotoxic agents, or other biologics was
prohibited.

655 Study RA-3 evaluated 637 patients with active RA who were MTX-naïve and had not previously 656 been treated with a biologic TNF-blocker. Patients were randomized to receive MTX (n = 160), 657 SIMPONI 50 mg + MTX (n = 159), SIMPONI 100 mg + MTX (n = 159), or SIMPONI 100 mg 658 monotherapy (n = 159). For patients receiving MTX, MTX was administered at a dose of 10 659 mg/week beginning at Week 0 and increased to 20 mg/week by Week 8. The use of other 660 DMARDs including SSZ, HCO, cytotoxic agents, or other biologics was prohibited.

661

665

The primary endpoint in Study RA-1 and Study RA-2 was the percentage of patients achieving an
ACR 20 response at Week 14 and the primary endpoint in Study RA-3 was the percentage of
patients achieving an ACR 50 response at Week 24.

In Studies RA-1, RA-2, and RA-3, the median duration of RA disease was 9.4, 5.7, and 1.2 years;
and 99%, 75%, and 54% of the patients used at least one DMARD in the past, respectively.
Approximately 77% and 57% of patients received concomitant NSAIDs and low dose
corticosteroids, respectively, in the 3 pooled RA trials.

671 *Clinical Response*

672 In the 3 RA trials, a greater percentage of patients treated with the combination of SIMPONI and 673 MTX achieved ACR responses at Week 14 (Studies RA-1 and RA-2) and Week 24 (Studies RA-1, RA-2, and RA-3) versus patients treated with the MTX alone. There was no clear evidence of 674 675 improved ACR response with the higher SIMPONI dose group (100 mg) compared to the lower 676 SIMPONI dose group (50 mg). In Studies RA-2 and RA-3, the SIMPONI monotherapy groups 677 were not statistically different from the MTX monotherapy groups in ACR responses. Table 2 678 shows the proportion of patients with the ACR response for the SIMPONI 50 mg and control 679 groups in Studies RA-1, RA-2, and RA-3. In the subset of patients who received SIMPONI in 680 combination with MTX in Study RA-1, the proportion of patients achieving ACR 20, 50 and 70 681 responses at week 14 were 40%, 18%, and 12%, respectively, in the SIMPONI 50 mg + MTX 682 group (N = 101) compared with 17%, 6%, and 2%, respectively, in the placebo + MTX group (N 683 = 103). Table 3 shows the percent improvement in the components of the ACR response criteria 684 for the SIMPONI 50 mg + MTX and MTX groups in Study RA-2. The percent of patients 685 achieving ACR 20 responses by visit for Study RA-2 is shown in Figure 1. ACR 20 responses 686 were observed in 38% of patients in the SIMPONI 50 mg + MTX group at the first assessment 687 (Week 4) after the initial SIMPONI administration.

689 690

Table 2. Studies RA-1, RA-2, and RA-3 Proportion of Patients with an ACR Response^a

	Study RA-1 Active RA previously treated with one or more doses of TNF-blockers		Study RA-2 Active RA, despite MTX		Study RA-3 Active RA, MTX Naïve	
	Placebo	SIMPONI				
	±	$50 \text{ mg} \pm$	Background	SIMPONI 50 mg +		SIMPONI 50 mg +
	DMARDs ^b	DMARDs ^b	MTX	Background MTX	MTX	MTX
N ^c	150	147	133	89	160	159
ACR 20						
Week 14	18%	35%	33%	55%	NA ^e	NA ^e
Week 24	16%	31%	28%	60%	49%	62%
ACR 50						
Week 14	7%	15%	10%	35%	NA ^e	NA ^e
Week 24	4%	16%	14%	37%	29%	40%
ACR 70						
Week 14	2%	10%	4%	13%	NA ^e	NA ^e
Week 24	2%	9%	5%	20%	16%	24% ^d
a A	pproximately '	78% and 58% of the	patients receiv	ed concomitant NSAID	s and low do	se corticosteroids
 (equivalent to ≤ 10 mg of prednisone a day), respectively, during the 3 pooled RA trials. DMARDs in Study RA-1 included MTX, HCQ, and/or SSZ (about 68%, 8%, and 5% of patients received MTX, HCQ, and SSZ, respectively). 						
	reflects randomized patients.					
d N	lot significantly different from MTX monotherapy.					

 e NA = Not applicable, as data was not collected at Week 14 in Study RA-3.

691 692

Table 3. Study RA-2 – Median Percent Improvement from Baseline in the Individual ACR Components at Week 14^a

693 694

	Background MTX	SIMPONI 50 mg + Background MTX
N ^b	133	89
Number of swo	llen joints (0-66)	
Baseline	12	13
Week 14	38%	62%
Number of ten	der joints (0-68)	
Baseline	21	26
Week 14	30%	60%
Patient's assess	sment of pain (0-10)	
Baseline	5.7	6.1
Week 14	18%	55%
Patient's globa	l assessment of disease activity	(0-10)
Baseline	5.3	6.0
Week 14	15%	45%
Physician's glo	bal assessment of disease activity	ty (0-10)
Baseline	5.7	6.1
Week 14	35%	55%
HAQ score (0-3	3)	
Baseline	1.25	1.38
Week 14	10%	29%
CRP (mg/dL)		
Baseline	0.8	1.0
Week 14	2%	44%
Note: Baseline va	lues are medians.	


iedians.

а In Study RA-2, about 70% and 85% of patients received concomitant low dose corticosteroids (equivalent to ≤ 10 mg of prednisone a day) and/or NSAIDs during the trials, respectively.

b N reflects randomized patients; actual number of patients evaluable for each endpoint may vary.

Figure 1. Study RA - 2 – Percent of Patients Achieving ACR 20 Response by Visit: Randomized
 Patients*

700



The same patients may not have responded at each timepoint.

- 701 702
- 703
- 704 705

713

706 Physical Function Response in Patients with RA

In Studies RA-1 and RA-2, the SIMPONI 50 mg groups demonstrated a greater improvement
compared to the control groups in the change in mean Health Assessment Questionnaire Disability
Index (HAQ-DI) score from baseline to Week 24: 0.23 vs. 0.03 in RA-1, 0.47 vs. 0.13 in RA-2,
respectively. Also in Studies RA-1 and RA-2, the SIMPONI 50 mg groups compared to the
control groups had a greater proportion of HAQ responders (change from baseline > 0.22) at
Week 24: 43% vs. 27%, 65% vs. 35%, respectively.

714 **14.2 Psoriatic Arthritis**

715 The safety and efficacy of SIMPONI were evaluated in a multi-center, randomized, double-blind, 716 placebo-controlled trial in 405 adult patients with moderately to severely active PsA (\geq 3 swollen joints and \geq 3 tender joints) despite NSAID or DMARD therapy (Study PsA). Patients in this 717 study had a diagnosis of PsA for at least 6 months with a qualifying psoriatic skin lesion of at least 718 2 cm in diameter. Previous treatment with a biologic TNF-blocker was not allowed. Patients 719 720 were randomly assigned to placebo (n = 113), SIMPONI 50 mg (n = 146), or SIMPONI 100 mg 721 (n = 146) given subcutaneously every 4 weeks. Patients were allowed to receive stable doses of concomitant MTX (≤ 25 mg/week), low dose oral corticosteroids (equivalent to ≤ 10 mg of 722 723 prednisone a day), and/or NSAIDs during the trial. The use of other DMARDs including SSZ, 724 HCQ, cytotoxic agents, or other biologics was prohibited. The primary endpoint was the 725 percentage of patients achieving ACR 20 response at Week 14. Placebo-controlled efficacy data 726 were collected and analyzed through Week 24. 727

Patients with each subtype of PsA were enrolled, including polyarticular arthritis with no
rheumatoid nodules (43%), asymmetric peripheral arthritis (30%), distal interphalangeal (DIP)

730 joint arthritis (15%), spondylitis with peripheral arthritis (11%), and arthritis mutilans (1%). The 731 median duration of PsA disease was 5.1 years, 78% of patients received at least one DMARD in 732 the past, and approximately 48% of patients received MTX, and 16% received low dose oral 733 steroids.

734 735 Clinical Response in Patients with PsA

736 SIMPONI \pm MTX, compared with placebo \pm MTX, resulted in significant improvement in signs 737 and symptoms as demonstrated by the proportion of patients with an ACR 20 response at Week 14 738 in Study PsA (see Table 4). There was no clear evidence of improved ACR response with the 739 higher SIMPONI dose group (100 mg) compared to the lower SIMPONI dose group (50 mg). 740 ACR responses observed in the SIMPONI-treated groups were similar in patients receiving and 741 not receiving concomitant MTX. Similar ACR 20 responses at Week 14 were observed in patients 742 with different PsA subtypes. However, the number of patients with arthritis mutilans was too 743 small to allow meaningful assessment. SIMPONI 50 mg treatment also resulted in significantly 744 greater improvement compared with placebo for each ACR component in Study PsA (Table 5). 745 Treatment with SIMPONI resulted in improvement in enthesitis and skin manifestations in 746 patients with PsA. However, the safety and efficacy of SIMPONI in the treatment of patients with 747 plaque psoriasis has not been established.

748 749 The percent of patients achieving ACR 20 responses by visit for Study PsA is shown in Figure 2.

750 751

752	
753	

Table 4. Study PsA - Proportion of Patients with ACR Respo			
	Placebo ± MTX ^a	SIMPONI 50 mg ± MTX ^a	
N ^b	113	146	
ACR 20			
Week 14	9%	51%	
Week 24	12%	52%	
ACR 50			
Week 14	2%	30%	
Week 24	4%	32%	
ACR 70			
Week 14	1%	12%	
Week 24	1%	19%	
doses of MTX ($\leq 10 \text{ mg of pred}$ ^b N reflects rando		steroids (equivalent to	
Bold text indicates	primary endpoint.		

ises

ACR 20 responses were observed in 31% of patients in the SIMPONI 50 mg + MTX group at the

first assessment (Week 4) after the initial SIMPONI administration.


	Placebo± MTX ^a	SIMPONI 50 mg ± MTX ^a
N ^b	113	146
Number of swollen joints (0-66)		
Baseline	10.0	11.0
Week 14	8%	60%
Number of tender joints (0-68)		
Baseline	18.0	19.0
Week 14	0%	54%
Patient's assessment of pain (0-10)		
Baseline	5.4	5.8
Week 14	-1%	48%
Patient's global assessment		
of disease activity (0-10)		
Baseline	5.2	5.2
Week 14	2%	49%
Physician's global assessment		
of disease activity (0-10)		
Baseline	5.2	5.4
Week 14	7%	59%
HAQ score (0-10)		
Baseline	1.0	1.0
Week 14	0%	28%
CRP (mg/dL) (0-10)		
Baseline	0.6	0.6
Week 14	0%	40%
Note: Baseline are median values.		

Table 5. Study PsA - Percent Improvement in ACR Components at Week 14

In Study PsA, about 48%, 16%, and 78% of the patients received stable doses of MTX (\leq 25 mg/day), low dose corticosteroids (equivalent to \leq 10 mg of prednisone a day), and NSAIDs, respectively.

b N reflects randomized patients; actual number of patients evaluable for each endpoint may vary by timepoint.

Figure 2. Study PsA – Percent of ACR 20 PsA Responders by Visit: Randomized Patients*



757 758

> 759 760 761

755

756

^{*} The same patients may not have responded at each timepoint.

Physical Function Response in Patients with PsA

In Study PsA, SIMPONI 50 mg demonstrated a greater improvement compared to placebo in the change in mean Health Assessment Questionnaire Disability Index (HAQ-DI) score from baseline to Week 24 (0.33 and -0.01, respectively). In addition, the SIMPONI 50 mg group compared to the placebo group had a greater proportion of HAQ responders (≥ 0.3 change from baseline) at Week 24: 43% vs. 22%, respectively.

767 768

14.3 Ankylosing Spondylitis

769 The safety and efficacy of SIMPONI were evaluated in a multi-center, randomized, double-blind, placebo-controlled trial in 356 adult patients with active ankylosing spondylitis according to 770 771 modified New York criteria for at least 3 months (Study AS). Patients had symptoms of active 772 disease [defined as a Bath AS Disease Activity Index (BASDAI) \geq 4 and VAS for total back pain 773 of \geq 4, on scales of 0 to 10 cm] despite current or previous NSAID therapy. Patients were 774 excluded if they were previously treated with a biologic TNF-blocker or if they had complete 775 ankylosis of the spine. Patients were randomly assigned to placebo (n = 78), SIMPONI 50 mg (n 776 = 138), or SIMPONI 100 mg (n = 140) administered subcutaneously every 4 weeks. Patients were allowed to continue stable doses of concomitant MTX, sulfasalazine (SSZ), hydroxychloroquine 777 778 (HCQ), low dose corticosteroids (equivalent to < 10 mg of prednisone a day), and/or NSAIDs 779 during the trial. The use of other DMARDs including cytotoxic agents or other biologics was 780 prohibited.

781

The primary endpoint was the percentage of patients achieving an ASsessment in Ankylosing
Spondylitis (ASAS) 20 response at Week 14. Placebo-controlled efficacy data were collected and
analyzed through Week 24.

In Study AS, the median duration of AS disease was 5.6 years, median duration of inflammatory
back pain was 12 years, 83% were HLA-B27 positive, 24% had prior joint surgery or procedure,
and 55% received at least one DMARD in the past. During the trial, the use of concomitant
DMARDs and/or NSAIDs was as follows: MTX (20%), SSZ (26%), HCQ (1%), low dose oral
steroids (16%), and NSAIDs (90%).

791

792 Clinical Response in Patients with AS

In Study AS, SIMPONI \pm DMARDs treatment, compared with placebo \pm DMARDs, resulted in a significant improvement in signs and symptoms as demonstrated by the proportion of patients with an ASAS 20 response at Week 14 (see Table 6). There was no clear evidence of improved ASAS response with the higher SIMPONI dose group (100 mg) compared to the lower SIMPONI dose group (50 mg). Table 7 shows the percent improvement in the components of the ASAS response criteria for the SIMPONI 50 mg \pm DMARDs and placebo \pm DMARDs groups in Study AS.

The percent of patients achieving ASAS 20 responses by visit for Study AS is shown in Figure 3.
ASAS 20 responses were observed in 48% of patients in the SIMPONI 50 mg + MTX group at the
first assessment (Week 4) after the initial SIMPONI administration.

803

799

804

805

Table 6. Study AS – Proportion of ASAS Responders at Weeks 14 and 24

	Placebo ± DMARDs ^a	SIMPONI 50 mg ± DMARDs ^a
N ^b	78	138
Responders, % of p	patients	
ASAS 20		
Week 14	22%	59%
Week 24	23%	56%
ASAS 40		
Week 14	15%	45%
Week 24	15%	44%
-	e concomitant use of stable doses of DMA, and HCQ (1%). About 16% and 89% of	

of low dose oral steroids and NSAIDs during the trial, respectively.

^b N reflects randomized patients.

Bold text indicates primary endpoint.

Table 7. Study AS – Median Percent Improvement in ASAS Components at Week 14

806 807

	Placebo ± DMARDs ^a	SIMPONI 50 mg ± DMARDs ^a
N ^b	78	138
ASAS components		
Patient global assessment (0-10)		
Baseline	7.2	7.0
Week 14	13%	47%
Total back pain (0-10)		
Baseline	7.6	7.5
Week 14	9%	50%
BASFI (0-10) ^c		
Baseline	4.9	5.0
Week 14	-3%	37%
Inflammation (0-10) ^d		
Baseline	7.1	7.1
Week 14	6%	59%

^a During the trial, the concomitant use of stable doses of DMARDS was as follows: MTX (21%), SSZ (25%), and HCQ (1%). About 16% and 89% of patients received stable doses of low dose oral steroids and NSAIDs during the trial, respectively.

^b N reflects randomized patients.

^c BASFI is Bath Ankylosing Spondylitis Functional Index.


^d Inflammation is the mean of two patient-reported stiffness self-assessments in the Bath AS Disease Activity Index (BASDAI).

808 809

810

- 811
- 812

Figure 3. Study AS – Percent of AS Patients Achieving ASAS 20 Response by Visit: Randomized Patients^{*}



813 814

* The same patients may not have responded at each timepoint.

815

819 820

824

826

827

828

816 **15 REFERENCES**

817 1. SEER [database online]. US Population Data – 1969-2004. Bethesda, MD: National Cancer
 818 Institute. Release date: January 3, 2007. Available at: http://seer.cancer.gov/popdata/.

16 HOW SUPPLIED/STORAGE AND HANDLING

Each SIMPONI prefilled autoinjector or prefilled syringe is packaged in a light-blocking,
cardboard outer carton. SIMPONI is available in packs of 1 prefilled syringe NDC 57894-070-01
or 1 prefilled SmartJect autoinjector NDC 57894-070-02.

825 Prefilled SmartJect Autoinjector

Each single dose SmartJect autoinjector contains a prefilled glass syringe (27 gauge ¹/₂ inch) providing 50 mg of SIMPONI per 0.5 mL of solution.

829 **Prefilled Syringe**

Each single dose prefilled glass syringe (27 gauge ½ inch) contains 50 mg of SIMPONI per 0.5
mL of solution.

832 833

Storage and Stability

834 SIMPONI must be refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light. Keep the 835 product in the original carton to protect from light until the time of use. Do not freeze. Do not 836 shake. Do not use SIMPONI beyond the expiration date (EXP) on the carton or the expiration 837 date on the prefilled syringe (observed through the viewing window) or the prefilled SmartJect 838 autoinjector.

839 840

841

842 843

844

845

846

847

17 PATIENT COUNSELING INFORMATION

See FDA-Approved Patient Labeling (Medication Guide and Patient Instructions for Use)

17.1 Patient Counseling

Patients should be advised of the potential benefits and risks of SIMPONI. Physicians should instruct their patients to read the Medication Guide before starting SIMPONI therapy and to read it each time the prescription is renewed.

848 Infections

Inform patients that SIMPONI may lower the ability of their immune system to fight infections.
 Instruct the patient of the importance of contacting their doctor if they develop any symptoms of
 infection, including tuberculosis, invasive fungal infections, and hepatitis B reactivation.

853 Malignancies

Patients should be counseled about the risk of lymphoma and other malignancies while receivingSIMPONI.

856

857 Allergic Reactions

Advise latex-sensitive patients that the needle cover on the prefilled syringe as well as the prefilled syringe in the prefilled SmartJect autoinjector contains dry natural rubber (a derivative of latex).

861 *Other Medical Conditions*

865

872

876

879

882

888

Advise patients to report any signs of new or worsening medical conditions such as congestive
heart failure, demyelinating disorders, autoimmune diseases, liver disease, cytopenias, or
psoriasis.

866 **17.2 Instruction on Injection Technique**

The first self-injection should be performed under the supervision of a qualified healthcare professional. If a patient or caregiver is to administer SIMPONI, he/she should be instructed in injection techniques and their ability to inject subcutaneously should be assessed to ensure the proper administration of SIMPONI (*see FDA-Approved Patient Labeling (Medication Guide and Patient Instructions for Use)*).

Prior to use, remove the prefilled syringe or the prefilled SmartJect autoinjector from the
refrigerator and allow SIMPONI to sit at room temperature outside of the carton for 30 minutes
and out of the reach of children.

Bo not warm SIMPONI in any other way. For example, do not warm SIMPONI in a microwaveor in hot water.

Bo not remove the prefilled syringe needle cover or SmartJect autoinjector cap while allowing
SIMPONI to reach room temperature. Remove these immediately before injection.

Do not pull the autoinjector away from the skin until you hear a first "click" sound and then a
second "click" sound (the injection is finished and the needle is pulled back). It usually takes
about 3 to 6 seconds but may take up to 15 seconds for you to hear the second "click" after the
first "click". If the autoinjector is pulled away from the skin before the injection is completed, a
full dose of SIMPONI may not be administered.

A puncture-resistant container for disposal of needles and syringes should be used. Patients or
 caregivers should be instructed in the technique of proper syringe and needle disposal, and be
 advised not to reuse these items.

- 892
 893
 894 Manufactured by:
 895 Janssen Biotech, Inc.
 896 Horsham, PA 19044
- 897 US License No. 1864
- 898
- 899 © Janssen Biotech, Inc. 2011

900	
901	
902	MEDICATION GUIDE
903	SIMPONI [®] (SIM-po-nee)
904	(golimumab)
905	
906	Read the Medication Guide that comes with SIMPONI before you start taking it and each time
907	you get a refill. There may be new information. This Medication Guide does not take the place of
908	talking with your doctor about your medical condition or treatment. It is important to remain
909	under your doctor's care while using SIMPONI.
910	
911	What is the most important information I should know about SIMPONI?
912	SIMPONI is a medicine that affects your immune system. SIMPONI can lower the ability of your
913	immune system to fight infections. Some people have serious infections while taking SIMPONI,
914	including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that spread
915	throughout their body. Some people have died from these serious infections.
916	 Your doctor should test you for TB and hepatitis B before starting SIMPONI.
917	• Your doctor should monitor you closely for signs and symptoms of TB during treatment
918	with SIMPONI.
919	
920	You should not start taking SIMPONI if you have any kind of infection unless your doctor says it
921	is okay.
922	
923	Before starting SIMPONI, tell your doctor if you:
924	 think you have an infection or have symptoms of an infection such as:
	 fever, sweat, or chills warm, red, or painful skin or sores on your body
	 muscle aches diarrhea or stomach pain
	 cough burning when you urinate or urinate more often
	• shortness of breath than normal
	 blood in phlegm feel very tired
	• weight loss
925	
926	• are being treated for an infection
927	• get a lot of infections or have infections that keep coming back
928	• have diabetes, HIV, or a weak immune system. People with these conditions have a higher
929	chance for infections.
930	 have TB, or have been in close contact with someone with TB
931	 live, have lived, or traveled to certain parts of the country (such as the Ohio and
932	Mississippi River valleys and the Southwest) where there is an increased chance for getting
933	certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, blastomycosis).
	· · · · · · · · · · · · · · · · · · ·
933 934 935 936 937 938	 These infections may happen or become more severe if you use SIMPONI. Ask your doctor if you do not know if you have lived in an area where these infections are common. have or have had hepatitis B use the medicine ORENCIA (abatacept), KINERET (anakinra), ACTEMRA (tocilizumab) or RITUXAN (rituximab)

000	
939	
940	After starting SIMPONI, call your doctor right away if you have any symptoms of an
941	infection. SIMPONI can make you more likely to get infections or make worse any infection
942	that you have.
943	
944	Cancer
945	• For children and adults taking TNF-blocker medicines, including SIMPONI, the chances of
946	getting cancer may increase.
947	• There have been cases of unusual cancers in children and teenage patients taking TNF-
948	blocking agents.
949	People with inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, or
950	ankylosing spondylitis, especially those with very active disease, may be more likely to get
951	lymphoma.
952	
953	What is SIMPONI?
954	SIMPONI is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker. SIMPONI is
955	used in adults:
956	• with the medicine methotrexate to treat moderately to severely active rheumatoid arthritis (RA)
957	 to treat active psoriatic arthritis (PsA) alone or with methotrexate
958	• to treat active ankylosing spondylitis (AS)
959	
960	You may continue to use other medicines that help treat your condition while taking SIMPONI, such
961	as non-steroidal anti-inflammatory drugs (NSAIDs) and prescription steroids, as recommended by
962	your doctor.
963 964	What should I tell my doctor before starting treatment with SIMPONI?
964 965	SIMPONI may not be right for you. Before starting SIMPONI, tell your doctor about all your medical
965 966	conditions, including if you:
967	 have an infection (see "What is the most important information I should know about SIMPONI?").
967 968	
908 969	
970 071	 have or have had a condition that affects your nervous system, such as multiple sclerosis or
971 072	Guillain-Barré syndrome.
972 072	• have recently received or are scheduled to receive a vaccine. People taking SIMPONI should not
973 074	receive live vaccines. People taking SIMPONI can receive non-live vaccines.
974 075	• have a baby and you were using SIMPONI during your pregnancy. Tell your baby's doctor before
975 076	your baby receives any vaccine. Your baby may have an increased chance of getting an infection
976 077	for up to 6 months after birth.
977 078	• are allergic to rubber or latex. The needle cover on the prefilled syringe and SmartJect [®]
978 070	autoinjector contains dry natural rubber.
979 080	• are pregnant or planning to become pregnant. It is not known if SIMPONI will harm your unborn
980 081	baby.
981	• are breastfeeding. You and your doctor should decide if you will take SIMPONI or breastfeed.
982 983	You should not do both without talking to your doctor first.
703	

Tell your doctor about all the medicines you take, including prescription and non-prescription
 medicines, vitamins, and herbal supplements. Especially, tell your doctor if you:

- 986 use ORENCIA (abatacept) or KINERET (anakinra). You should not take SIMPONI while you are
 987 also taking ORENCIA (abatacept) or KINERET (anakinra).
- use other TNF-blocker medicines, including REMICADE (infliximab), HUMIRA (adalimumab),
 ENBREL (etanercept), or CIMZIA (certolizumab pegol).
- 990 receive RITUXAN (rituximab) or ACTEMRA (tocilizumab).
- 991
- Ask your doctor if you are not sure if your medicine is one listed above.
- Keep a list of all your medications with you to show your doctor and pharmacist each time you get anew medicine.
- 996

997 How should I use SIMPONI?

- SIMPONI is given as an injection under the skin (subcutaneous injection).
- SIMPONI should be injected one time each month.
- If your doctor decides that you or a caregiver may be able to give your injections of SIMPONI at home, you should receive training on the right way to prepare and inject SIMPONI. Do not try to inject SIMPONI yourself until you have been shown the right way to give the injections by your doctor or nurse.
- Use SIMPONI exactly as prescribed by your doctor.
- SIMPONI comes in a prefilled syringe or SmartJect autoinjector. Your doctor will prescribe the type that is best for you.
- See the detailed *Patient Instructions for Use* at the end of this Medication Guide for instructions about the right way to prepare and give your SIMPONI injections at home.
- Do not miss any doses of SIMPONI. If you forget to use SIMPONI, inject your dose as soon as you remember. Then, take your next dose at your regular scheduled time. In case you are not sure when to inject SIMPONI, call your doctor or pharmacist.

1013 What are the possible side effects with SIMPONI?

- 1014 SIMPONI can cause serious side effects, including:
- 1015

1012

1016 See "What is the most important information I should know about SIMPONI?"

1017

1018 Hepatitis B infection in people who carry the virus in their blood.

- If you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus can become active while you use SIMPONI. Your doctor should do blood tests before you start treatment with SIMPONI and while you are using SIMPONI. Tell your doctor if you have any of the following symptoms of a possible hepatitis B infection:
 - feel very tired
- clay-colored bowel movements

- dark urine
- skin or eyes look yellow
- little or no appetite
- vomiting
- muscle aches

- fevers
- chills
- stomach discomfort
- skin rash

Heart failure, including new heart failure or worsening of heart failure that you already have. 1025 New or worse heart failure can happen in people who use TNF-blocker medicines including 1026 SIMPONI. 1027 • If you have heart failure, your condition should be watched closely while you take SIMPONI. 1028 • Call your doctor right away if you get new or worsening symptoms of heart failure while taking 1029 SIMPONI (such as shortness of breath or swelling of your lower legs or feet). 1030 1031 **Nervous System Problems** 1032 Rarely, people using TNF-blocker medicines, including SIMPONI, have nervous system problems 1033 such as multiple sclerosis or Guillain-Barré syndrome. 1034 Tell your doctor right away if you get any of these symptoms: • 1035 • vision changes 1036 • weakness in your arms or legs 1037 • numbress or tingling in any part of your body 1038 1039 **Liver Problems** 1040 Liver problems can happen in people who use TNF-blocker medicines, including SIMPONI. These problems can lead to liver failure and death. Call your doctor right away if you have any of these 1041 1042 symptoms: 1043 • feel very tired 1044 • skin or eyes look yellow 1045 poor appetite or vomiting • 1046 pain on the right side of your stomach (abdomen) • 1047 1048 **Blood Problems** 1049 Low blood counts have been seen with TNF-blockers, including SIMPONI. Your body may not make enough blood cells that help fight infections or help stop bleeding. Symptoms include fever, bruising 1050 1051 or bleeding easily, or looking pale. Your doctor will check your blood counts before and during 1052 treatment with SIMPONI. 1053 1054 **Common side effects with SIMPONI include:** 1055 1056 • upper respiratory infection (runny nose, sore throat, and hoarseness or laryngitis) reaction at the site of injection (redness, swelling, itching, pain, bruising, or tingling) 1057 • 1058 viral infections such as flu and oral cold sores • 1059 1060 Other side effects with SIMPONI include: 1061 1062 • Immune System Problems. Rarely, people using TNF-blocker medicines have developed 1063 symptoms that are like the symptoms of Lupus. Tell your doctor if you have any of these 1064 symptoms: 1065 • a rash on your cheeks or other parts of the body 1066 • sensitivity to the sun • new joint or muscle pains 1067

1068	becoming very tired
1069	chest pain or shortness of breath
1070	• swelling of the feet, ankles, or legs
1071	
1072	• Psoriasis. Some people using SIMPONI had new psoriasis or worsening of psoriasis they already
1073	had. Tell your doctor if you develop red scaly patches or raised bumps that are filled with pus.
1074	Your doctor may decide to stop your treatment with SIMPONI.
1075	
1076	• Allergic Reactions. Allergic reactions can happen in people who use TNF-blocker medicines
1077	including SIMPONI. Some reactions may be serious and can be life-threatening. Some of these
1078	reactions can happen after receiving your first dose of SIMPONI. Call your doctor right away if
1079	you have any of these symptoms of an allergic reaction:
1080	• hives
1081	• swollen face
1082	• breathing trouble
1082	 chest pain
1085	• chest pain
1085	These are not all of the side effects with SIMPONI. Tell your doctor about any side effect that bothers
1086	you or does not go away. Call your doctor for medical advice about side effects. You may report side
1087	effects to the FDA at 1-800-FDA-1088.
1088	
1089	How do I store SIMPONI?
1090	• Refrigerate SIMPONI at 36°F to 46°F (2°C to 8°C).
1091	• Do not freeze SIMPONI.
1092	• Keep SIMPONI in the carton to protect it from light when not being used.
1093	• Do not shake SIMPONI.
1094	
1095	Keep SIMPONI and all medicines out of the reach of children.
1096	
1097	General Information about SIMPONI
1098	• Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide.
1099	Do not use SIMPONI for a condition for which it was not prescribed.
1100	• Do not give SIMPONI to other people, even if they have the same condition that you have. It may
1101	harm them.
1102	• This Medication Guide summarizes the most important information about SIMPONI. If you
1103	would like more information, talk to your doctor. You can ask your doctor or pharmacist for
1104	information about SIMPONI that is written for health professionals. For more information go to
1105	www.simponi.com or call 1-800-JANSSEN (1-800-526-7736).
1106	
1107	What are the ingredients in SIMPONI?
1108	Active ingredient: golimumab.
1109	Inactive ingredients: L-histidine, L-histidine monohydrochloride monohydrate, sorbitol, polysorbate
1110	80, and water for injection. SIMPONI does not contain preservatives.
1111	Manufactured by:
1112	Manufactured by:
1113	Janssen Biotech, Inc.

- 1114 Horsham, PA 19044
- 1115 US License No. 1864
- 1116
- 1117 © Janssen Biotech, Inc. 2011
- 1118
- 1119 Revised: 8/2011
- 1120 This Medication Guide has been approved by the U.S. Food and Drug Administration.